GV ‐971 attenuates α‐Synuclein aggregation and related pathology
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14393 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Zhenwei Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Mannose, Parkinson Disease, Synucleinopathies. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Rationale
Synucleinopathies, including Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB), share a distinct pathological feature, that is, a widespread accumulation of α‐synuclein (α‐syn) in the brain. There is a significant clinical unmet need for disease‐modifying treatments for synucleinopathies. Recently, a seaweed‐derived mixture of oligosaccharides sodium oligomannate, GV‐971, was approved for Phase 2 clinical trials for PD. This study aimed to further evaluate the therapeutic effects of GV‐971 on synucleinopathies using cellular and animal models and explore its associated molecular mechanisms. Methods α‐Syn aggregation was assessed, in vitro and ex vivo, by ThT assay. A dopaminergic neuron cell line, Prnp‐SNCA A53T mice, and brain slices from PD and DLB patients were used to determine the efficacy of GV‐971 in ameliorating α‐syn pathology. Measurements of motor functions, including pole, cylinder, and rotarod tests, were conducted on Prnp‐SNCA A53T mice 4 weeks after intragastric administration of GV‐971 (200 mg day −1 kg −1 ).
Results
GV‐971 effectively prevented α‐syn aggregation and even disassembled pre‐aggregated α‐syn fibrils, in vitro and ex vivo . In addition, GV‐971 was able to rescue α‐syn‐induced neuronal damage and reduced release of extracellular vesicles (EVs), likely via modulating Alix expression. In the Prnp‐SNCA A53T mouse model, when treated at the age of 5 months, GV‐971 significantly decreased α‐syn deposition in the cortex, midbrain, and cerebellum regions, along with ameliorating the motor dysfunctions.
Conclusions
Our results indicate that GV‐971, when administered at a relatively early stage of the disease process, significantly reduced α‐syn accumulation and aggregation in Prnp‐SNCA A53T mice. Furthermore, GV‐971 corrected α‐syn‐induced inhibition of EVs release in neurons, contributing to neuronal protection. Future studies are needed to further assess GV‐971 as a promising disease‐modifying therapy for PD and other synucleinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
- Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- National Health and Disease Human Brain Tissue Resource Center, Zhejiang University, Hangzhou, China.
- AliveX Biotech, Shanghai, China.
- Department of Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
- Department of Pathology, Peking University Health Science Center and Third Hospital, Beijing, China.
ORCID-Profile: Jing Zhang
Förderung
- NIA NIH HHS
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- Alzheimer’s Disease Research Center, University of Washington
Zitieren
APA
Yu, Z., Yang, Y., Chan, R. B., Shi, M., Stewart, T., Huang, Y., Liu, Z., Lan, G., Sheng, L., Tian, C., Yang, D., & Zhang, J. (2024). GV ‐971 attenuates α‐Synuclein aggregation and related pathology. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14393
Vancouver
Yu Z, Yang Y, Chan RB, Shi M, Stewart T, Huang Y, et al. GV ‐971 attenuates α‐Synuclein aggregation and related pathology. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14393
BibTeX
@article{Yu2024,
author = {Yu, Zhenwei and Yang, Ying and Chan, Robin Barry and Shi, Min and Stewart, Tessandra and Huang, Yang and Liu, Zongran and Lan, Guoyu and Sheng, Lifu and Tian, Chen and Yang, Dishun and Zhang, Jing},
title = {GV ‐971 attenuates α‐Synuclein aggregation and related pathology},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14393}
}
EUVIMED